Photo-activated microtubule targeting drugs: Advancing therapies for colorectal cancer.

World J Gastroenterol

Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, United States.

Published: July 2024

AI Article Synopsis

  • Immunotherapy has significantly advanced cancer treatment, but long-term survival for colorectal cancer patients is still a major challenge.
  • Combination treatments using targeted drugs like MEK inhibitors have provided some relief, but more effective therapies are needed.
  • Recent interest is growing in innovative methods, such as light-activated drugs and optical devices, which could enable precise delivery of cancer-fighting agents directly to tumor cells in the colon.

Article Abstract

Over the years immunotherapy has demonstrably improved the field of cancer treatment. However, achieving long-term survival for colorectal cancer (CRC) patients remains a significant unmet need. Combination immunotherapies incorporating targeted drugs like MEK or multi-kinase inhibitors have offered some palliative benefit. Nevertheless, substantial gaps remain in the current therapeutic armamentarium for CRC. In recent years, there has been a surge of interest in exploring novel treatment strategies, including the application of light-activated drugs in conjunction with optical devices. This approach holds promise for achieving localized and targeted delivery of cytotoxic agents, such as microtubule-targeting drugs, directly to cancerous cells within the colon.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287401PMC
http://dx.doi.org/10.3748/wjg.v30.i26.3257DOI Listing

Publication Analysis

Top Keywords

colorectal cancer
8
photo-activated microtubule
4
microtubule targeting
4
drugs
4
targeting drugs
4
drugs advancing
4
advancing therapies
4
therapies colorectal
4
cancer years
4
years immunotherapy
4

Similar Publications

Objectives: PD15, a novel natural steroidal saponin extracted from the rhizomes of Paris delavayi Franchet, has demonstrated a strong cytotoxic effect against HepG2 and U87MG cells. However, its therapeutic effects on colorectal cancer (CRC) and the underlying molecular mechanisms remain unclear.

Methods: MTT assay, clonogenic assay, Hoechst 33258 staining, flow cytometry, molecular docking, and western blot were used to investigate the mechanism of PD15 in HCT116 cell lines.

View Article and Find Full Text PDF

To evaluate the use of yttrium-90 (Y90) dosimetry in predicting treatment outcomes when used following transarterial radioembolization with SIR-Spheres® (Resin Y90) in patients with hepatic tumors. This single institution retrospective analysis included 100 patients with hepatocellular carcinoma, colorectal carcinoma or other liver metastases who underwent transarterial radioembolization with resin Y90 and had imaging follow-up within one year of treatment. Mean tumor dose and mean dose to nontumor was calculated using voxel-based dosimetry software.

View Article and Find Full Text PDF

Purpose: Identifying therapeutic targets for Signet Ring Cell Carcinoma (SRCC) of the colon and rectum is a clinical challenge due to the lack of Patient-Derived Organoids (PDO) or Xenografts (PDX). We present a robust method to establish PDO and PDX models to answer address this unmet need. We demonstrate that these models identify novel therapeutic strategies targeting therapy resistance and peritoneal metastasis.

View Article and Find Full Text PDF

The emergence of Next Generation Sequencing (NGS) technology has catalyzed a paradigm shift in clinical diagnostics and personalized medicine, enabling unprecedented access to high-throughput microbiome data. However, the inherent high dimensionality, noise, and variability of microbiome data present substantial obstacles to conventional statistical methods and machine learning techniques. Even the promising deep learning (DL) methods are not immune to these challenges.

View Article and Find Full Text PDF

Colorectal cancer (CRC) is the second leading cause of cancer-related mortality globally. While immunotherapeutic approaches are effective in a subset of CRC patients, the majority of CRC cases receive limited benefits from immunotherapy. This study developed an immune subtype classification system based on diverse immune cells and pathways.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!